Background
==========

Gastrointestinal cancers (GICs) are the most frequently diagnosed cancers of the digestive tract system and are the leading cause of cancer death in men and women worldwide.[@b1-ott-11-351],[@b2-ott-11-351] Esophageal cancer (EC), gastric cancer (GC), colorectal cancer (CRC), pancreatic cancer (PC), hepatocellular carcinoma (HCC), and gallbladder carcinoma (GBC) are the major malignancies of GICs. It has been reported that GICs account for 30% of the global incidence and 40% of the global malignant tumor mortality.[@b3-ott-11-351] CRC and HCC are the third and fifth most frequent cancers, whereas EC and GC are relatively rare but have poorer prognosis, with 18.4% and 30.4% 5-year survival rate in the USA, respectively.[@b2-ott-11-351],[@b4-ott-11-351] GBC is a rare gastrointestinal malignancy, but it is the most common malignant tumor of the biliary tract worldwide.[@b5-ott-11-351],[@b6-ott-11-351] Although progression has been made in tumor diagnosis and treatment, the clinical outcome of GICs remains disappointed. This is generally because there is still a lack of effective early diagnosis methods, and most GIC patients develop cancer into an advanced stage at the time of diagnosis. Therefore, prognostic and predictive factors are urgently needed for cancer patients to guide clinical decision.

Heat shock proteins (HSPs) are a set of highly conserved proteins, which were first discovered as stress-inducible proteins.[@b7-ott-11-351] Under physiological conditions, HSPs are expressed at low levels and function as molecular chaperones that mediate cell growth, apoptosis, protein homeostasis, and cellular targets of peptides.[@b8-ott-11-351] HSPs have been classified into various subfamilies according to their molecular weight or systematic gene symbols.[@b9-ott-11-351],[@b10-ott-11-351] Broadly, the main HSPs are currently classified into five families, including HSP110, HSP90, HSP70, HSP60, and the small HSPs.[@b11-ott-11-351] Aberrant expression of HSPs has been reported in a wide range of human tumors, including breast, endometrial, ovarian, colon, lung, and prostate tumors.[@b12-ott-11-351] Recent studies have shown that the expression of HSPs is closely related to prognosis of cancers. The aim of this paper was to more precisely estimate the relationship between expression of multiple HSPs and prognosis of patients and investigate the possible utility of HSPs as prognostic biomarkers in GIC patients.

Materials and methods
=====================

Search strategy and study selection
-----------------------------------

The literature relevant to expression of HSPs and survival in gastrointestinal tumors were searched in PubMed, Cochrane Library, Web of Science, and Embase databases. The search ended in October 1, 2017. The search terms included the following keywords in various combinations: heat shock protein, HSP, stress protein, esophageal neoplasms, stomach neoplasms, colorectal neoplasms, hepatocellular neoplasms, pancreatic neoplasms, and gallbladder cancer. The references list of included studies and reviews was further sifted to identify additional potentially relevant studies.

To be eligible for inclusion in this meta-analysis, studies were required to meet the following criteria: 1) the study was published in English with the full text available; 2) studies focused on GICs, including human primary EC, GC, CRC, HCC, PC, and GBC; 3) the definition of HSP positive was tested by immunohistochemistry (IHC); 4) HSPs as prognostic markers were used to predict the prognosis for cancer patients; and 5) studies provided hazard ratio (HR) and 95% CI or Kaplan--Meier survival curves with sufficient data to extract HRs and 95% CI.

The exclusion criteria for this study were as follows: 1) laboratory articles, reviews, case reports, conference abstracts, and letters; 2) nonhuman subject studies; 3) overlapping articles or ones with duplicate data; and 4) no data on survival or unable to calculate HRs based on data provided.

Data extraction and quality assessment
--------------------------------------

Two investigators searched and assessed the studies independently. Extracted data included first author's name, publication year, number of patients, region, type of cancer, cutoff value, follow-up time, and HRs with 95% CI for overall survival (OS). If the data extraction results were inconsistent, third-party adjudication was consulted to reach a consensus.

Newcastle--Ottawa Scale (NOS) was adopted to assess the quality of included studies. We regarded the study with an NOS score of ≥6 as of good quality, and the study with ≤5 score was considered as of poor quality. Studies considered to be of high quality were included in this meta-analysis.

Statistical analysis
--------------------

Statistical analysis was performed using RevMan 5.3 and Stata 12.0 software. Pooled estimates of HRs and 95% CI were used to evaluate the association between expression of HSPs and OS. The heterogeneity between studies was evaluated by *χ*^2^ and *I*^2^ test. When the result (*I*^2^\>50% or *p*\<0.05) indicated heterogeneity, the random-effects model was used for the meta-analysis. Otherwise, a fixed-effects model was used. The software Engauge Digitizer was used to extract the survival data from a Kaplan--Meier curve in some articles. HR \>1 implied a worse prognosis for the group with positive HSP expression and would be considered to be statistically significant if the 95% CI did not overlap 1. Publication bias was examined by the Begg's funnel plot test.

Results
=======

Study identification and characteristics
----------------------------------------

As shown by the search flow diagram ([Figure 1](#f1-ott-11-351){ref-type="fig"}), 24 studies (six EC, seven GC, four CRC, three PC, three HCC, and one GBC) involving a total of 3,413 patients (581 with EC, 1,453 with GC, 811 with CRC, 210 with PC, 251 with HCC, and 107 with GBC) were included in our meta-analysis based on selection criteria.[@b13-ott-11-351]--[@b36-ott-11-351] The included studies were published from 1999 to 2017, and sample sizes ranged from 41 to 458 patients. More than half of included studies were from East Asian countries. All of included studies received scores ≥6 in methodological assessments, which meant they had high quality. Characteristics of included studies are summarized in [Table 1](#t1-ott-11-351){ref-type="table"}.

Meta-analysis
-------------

In this study, we evaluated the correlation between expression of HSPs and OS time of patients with GICs. As shown in [Figure 2](#f2-ott-11-351){ref-type="fig"}, combining all included studies, expression of HSPs was not associated with the OS of GIC patients (HR=1.17, 95% CI=\[0.90, 1.52\], *p*=0.25). However, the expression of HSPs was significantly associated with worse OS of GC (HR=1.63, 95% CI=\[1.03, 2.57\], *p*=0.04) and CRC (HR=1.67, 95% CI=\[1.25, 2.24\], *p*=0.0006) patients. The pooled HRs of HSP27, HSP60, HSP70, and HSP90 showed that the expression of these HSPs could not act as an effective prognostic marker in GICs ([Figure 3](#f3-ott-11-351){ref-type="fig"}).

Subgroup analysis
-----------------

Subgroup analysis was performed on sample size, NOS score, and cutoff value to explore potential sources of heterogeneity. As seen in [Table 2](#t2-ott-11-351){ref-type="table"}, when samples were divided into subgroups, expression of HSPs was correlated with OS in the bigger sample size subgroup (n\>110; HR=1.46, 95% CI=\[1.09, 1.94\], *p*=0.01). However, there was heterogeneity of expression of HSPs in both the bigger and the small sample size subgroups. NOS score of studies did not influence the relationship between HSPs and OS. Again, there was heterogeneity in both subgroups. Additionally, when divided by cutoff values, there was no heterogeneity in the not reported group.

Publication bias and sensitivity analysis
-----------------------------------------

Begg's funnel plot was performed to evaluate publication bias. The funnel plot of the selected studies showed significant symmetry ([Figure 4A](#f4-ott-11-351){ref-type="fig"}). Sensitivity analysis indicated that no point estimate of the omitted individual dataset lay outside the 95% CI of the combined analysis based on the overall HR estimate of OS ([Figure 4B](#f4-ott-11-351){ref-type="fig"}). Thus, the results of this meta-analysis were reliable.

Discussion
==========

HSPs are a class of proteins that are ubiquitously distributed in organisms from prokaryotic organisms to eukaryotic organisms. HSPs were shown to be overexpressed in a broad range of tumors, and the expression of HSPs has been associated with tumor cell proliferation and differentiation, as well as with resistance to apoptosis and poor prognosis.[@b12-ott-11-351],[@b37-ott-11-351] Tumorigenesis is a complicated process involving a variety of mutation accumulation. As molecular chaperone, HSPs participate in the functional metabolism of tumor cells and protect tumor cells from harmful factors in the process of tumor formation.[@b38-ott-11-351] Certain HSPs can provide an immunogenic context to peptides that associate with them inside tumor or infected cells, which induces specific cytotoxic T-cell responses and protective immunity.[@b39-ott-11-351] Meanwhile, HSPs allow tumor cells to tolerate genetic alterations, which would otherwise be fatal.[@b40-ott-11-351]

GIC is one of the major health care problems in the world. Clinical parameters such as lymph node metastasis and TNM stage are generally considered as prognostic factors but are insufficient to provide useful information for clinical management. The expression of HSPs likely provides a crucial function in tumorigenesis and tumor invasion. However, the clinical evidence for this role of HSPs in GICs was inconclusive. Thus, we performed this meta-analysis to explore the prognostic value of HSPs for GICs.

In this study, we included 24 studies about the prognostic value of HSPs in GICs. The results suggested that positive expression of HSPs was not significantly correlated with OS for GICs. However, we found that the expression of HSPs was significantly associated with poor OS in GC and CRC patients.

Various molecular mechanisms involved in the carcinogenesis of HSPs have been investigated. Enhanced expression of HSPs during the progression of cancer cells implies its close relationship with the cell growth.[@b41-ott-11-351] In GC, blocking HSP90 disrupts EGFR, HER-2, and HIF-1A signaling pathways and inhibits cell proliferation in vitro and in vivo.[@b42-ott-11-351],[@b43-ott-11-351] It has been reported that HSP60 regulates apoptosis by direct interaction with cyclophilin D in the mitochondrial permeability transition pore, which reduces caspase-dependent apoptosis.[@b44-ott-11-351] A Phase II study of the tumor vaccine with HSPPC-96 reported that GC patients who received the vaccine had improved disease-free survival, and the 2-year OS rates were 81.9% and 67.9% for the gp96 vaccination and chemotherapy alone group, respectively.[@b45-ott-11-351] Expression of HSP27 in CRC cells enhances their apoptotic resistance in vitro and significantly increases their tumorigenicity in vivo.[@b46-ott-11-351] HSP27 is constitutively activated in CD133^+^ CRC stem cells, and HSP27 activation is required in CD133^+^ cells to prevent caspase-3 and caspase-9 cleavages in the apoptosis cascade. Inhibition of Hsp27 signaling sensitizes CD133^+^ cells to hypoxia and serum depletion-induced apoptosis.[@b47-ott-11-351] Hwang et al[@b48-ott-11-351] reported that compared with weakly metastatic colorectal cell lines, HSP70 expression was elevated in the highly metastatic cell line and HSP40 is colocalized with HSP70 in the nuclei and nucleoli of mammalian cells, where it interacts and cooperates with HSP70.[@b49-ott-11-351] HSP inhibitors can reduce the malignant biological function of tumor cells.[@b50-ott-11-351] In preclinical experiments, ganetespib has been shown to downregulate several HSP90 client proteins in CRC cells and lead to potent anticancer activity in vitro and in vivo.[@b51-ott-11-351],[@b52-ott-11-351] Together, these studies indicate that HSPs have a significant impact on prognosis of GC and CRC, which is consistent with our findings.

In this meta-analysis, there is significant heterogeneity in the analysis of prognostic value of HSPs. Although we conducted subgroup analysis and sensitivity analysis, the source of heterogeneity has not been fully explained. However, heterogeneity may be produced in the following aspects. First, all the included studies tested the expression of HSPs by IHC, differences in reagent and staining protocols, which may lead to a potential bias. Second, the cutoff value defining a section with positive HSP expression among the included studies is different, which also might produce heterogeneity. Third, due to the unified follow-up time, heterogeneity may be virtually brought in. Fourth, different types of cancers and inherent molecular differences might increase the heterogeneity. As eligible articles for meta-analysis were limited, more studies are still needed to provide more reliable evidence to evaluate the impact of expression of HSPs on clinical outcomes of GICs.

Limitations
-----------

Some limitations of our meta-analysis should be emphasized. First, only English literatures were included, due to the reason that literatures published in other languages were not available. Second, the number of included studies was limited, and only one study with gallbladder cancer was included in this meta-analysis, which may lead to a less powerful result in this meta-analysis. Third, more than half of included studies were carried out in Asian population; hence, it might be insufficient to draw conclusions that can be applied to all ethnic groups.

Conclusion
==========

Our meta-analysis suggests that a high level of HSPs may not be potential markers to predict survival rate for every type of GICs. However, expression of HSPs may predict a poor prognosis for GC and CRC patients. Owing to the limitations, additional studies related to tumor types are necessary to illuminate the clinical utility of increased HSPs in GICs.

**Disclosure**

The authors report no conflicts of interest in this work.
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![Forest plot of OS associated with the expression level of different HSPs in GIC patients.\
**Notes:** (**A**) Specific expression of HSPs in EC. (**B**) Specific expression of HSPs in GC. (**C**) Specific expression of HSPs in CRC. (**D**) Specific expression of HSP in PC. (**E**) Specific expression of HSPs in HCC. (**F**) Specific expression of HSPs in GBC.\
**Abbreviations:** OS, overall survival; GIC, gastrointestinal cancer; EC, esophageal cancer; GC, gastric cancer; CRC, colorectal cancer; PC, pancreatic cancer; HCC, hepatocellular carcinoma; GBC, gallbladder carcinoma; HR, hazard ratio; SE, standard error; IV, intravenous.](ott-11-351Fig2){#f2-ott-11-351}

![Forest plot of OS associated with specific HSPs in GIC patients.\
**Notes:** (**A**) HSP27 expression in GICs. (**B**) HSP60 expression in GICs. (**C**) HSP70 expression in GICs. (**D**) HSP90 expression in GICs.\
**Abbreviations:** OS, overall survival; GIC, gastrointestinal cancer; HR, hazard ratio; SE, standard error; IV, intravenous.](ott-11-351Fig3){#f3-ott-11-351}

![Publication bias and sensitivity analysis.\
**Notes:** (**A**) Begg's publication bias plot. (**B**) Chart of sensitivity analysis.\
**Abbreviations:** SE, standard error; HR, hazard ratio.](ott-11-351Fig4){#f4-ott-11-351}

###### 

Characteristics of studies included in the meta-analysis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                Year   Country   No of patients   Cancer type   Cutoff (%)   HSPs                    HR (95% CI)                              Recruitment time   Follow-up             NOS score
  ------------------------------------ ------ --------- ---------------- ------------- ------------ ----------------------- ---------------------------------------- ------------------ --------------------- -----------
  Shiozaki et al[@b13-ott-11-351]      2000   Japan     77               EC            10           HSP27: 88.3\            HSP27: 2.57 (0.59, 11.23)\               1990--1996         758.7 days (mean)     7
                                                                                                    HSP70: 79.2             HSP70: 3.17 (1.53, 6.55)                                                          

  Yu et al[@b14-ott-11-351]            2010   China     182              CRC           50           HSP27: 47.2             HSP27: 2.18 (1.38, 3.44)                 2004--2005         1--60 months          8

  Kanazawa et al[@b15-ott-11-351]      2003   Japan     50               CRC           NR           HSP70: 80.0\            HSP70: 0.09 (0.00, 9.68)\                NR                 NR                    6
                                                                                                    HSP40: 14.0             HSP40: 1.06 (0.07, 16.87)                                                         

  Faried et al[@b16-ott-11-351]        2004   Japan     123              EC            40           HSP90: 50.4\            HSP90: 0.92 (0.53, 1.64)\                1983--2002         NR                    7
                                                                                                    HSP60: 51.2             HSP60: 0.50 (0.26, 0.95)                                                          

  Huang et al[@b17-ott-11-351]         2014   China     72               EC            10           HSP90: 87.7             HSP90: 0.72 (0.23, 2.27)                 2004--2005         NR                    8

  Li et al[@b18-ott-11-351]            2014   China     223              GC            5            HSP60: 58.3             HSP60: 1.594 (1.114, 2.280)              2005--2008         4--82 months          9

  Lee et al[@b19-ott-11-351]           2013   Korea     210              GC            10           HSP70: 29.1             HSP70: 1.96 (0.44, 8.77)                 2002--2005         Up to February 2012   8

  Giaginis et al[@b20-ott-11-351]      2009   Greece    66               GC            5            HSP90: 50.0             HSP90: 0.50 (0.27, 0.92)                 NR                 1--104 months         8

  Wang et al[@b21-ott-11-351]          2013   China     157              GC            5            HSP90: 68.2             HSP90: 1.888 (1.022, 3.486)              2005--2011         4--82 months          9

  Wu et al[@b22-ott-11-351]            2009   Sweden    82               EC            25           HSP90: 72.0             HSP90: 1.11 (0.67, 1.84)                 1990--2000         NR                    7

  Wang et al[@b23-ott-11-351]          2012   China     175              CRC           5            HSP27: 55.3             HSP27: 2.020 (1.121, 3.643)              1993--2003         NR                    7

  Tweedle et al[@b24-ott-11-351]       2010   UK        404              CRC           5            HSP27: 43.6             HSP27: 1.37 (1.01, 1.86)                 1993--2003         0.23--146.5 months    8

  Kimura et al[@b25-ott-11-351]        2016   Japan     210              GC            NR           HSP110: 57.6            HSP110: 1.85 (1.05, 3.25)                NR                 NR                    8

  Kang et al[@b26-ott-11-351]          2013   Korea     458              GC            50           HSP70: 34.0             HSP70: 11.497 (1.388, 95.233)            2002--2005         2--2,514 days         9

  Kawanishi et al[@b27-ott-11-351]     1999   Japan     102              EC            80           HSP27: 79.6\            HSP27: 0.15 (0.04, 0.52)\                1989--1997         NR                    8
                                                                                                    HSP70: 31.1             HSP70: 0.37 (0.07, 2.11)                                                          

  Li et al[@b28-ott-11-351]            2014   China     129              GC            5            HSP22: 63.6             HSP22: 2.335 (1.335, 4.087)              2006--2007         3--82 months          9

  Nakajima et al[@b29-ott-11-351]      2009   Japan     125              EC            40           HSP70: 51.2             HSP70: 0.55 (0.27, 1.11)                 1983--2002         NR                    7

  Tsiaousidou et al[@b30-ott-11-351]   2013   Greece    41               PC            10           HSP27: 31.7             HSP27: 1.91 (0.66, 5.51)                 NR                 2--31 months          7

  Liu et al[@b31-ott-11-351]           2016   China     110              HCC           25           HSP70: 78.2             HSP70: 0.54 (0.13, 2.22)                 NR                 8--72 months          7

  Chen et al[@b32-ott-11-351]          2015   China     107              GBC           5            HSPgp96 (HSP90): 90.7   HSP gp96 (HSP90): 0.392 (0.181, 0.849)   2012--2014         NR                    6

  Schäfer et al[@b33-ott-11-351]       2012   Germany   89               PC            5            HSP27: 49.0             HSP27: 0.51 (0.31, 0.83)                 2003--2007         NR                    7

  Zhai et al[@b34-ott-11-351]          2017   China     80               PC            10           HSPA2 (HSP70): 68.5     HSPA2 (HSP70): 2.89 (0.80, 10.46)        2008--2011         3--42 months          8

  King et al[@b35-ott-11-351]          2000   Taiwan    58               HCC           25           HSP27: 48.3             HSP27: 2.24 (0.55, 9.06)                 NR                 NR                    6

  Kang et al[@b36-ott-11-351]          2014   Korea     83               HCC           5            HSP70: 52.7             HSP70: 1.45 (0.43, 4.89)                 1999--2011         2--135 months         8
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** HR, hazard ratio; NOS, Newcastle--Ottawa Scale; EC, esophageal cancer; CRC, colorectal cancer; NR, not reported; GC, gastric cancer; PC, pancreatic cancer; HCC, hepatocellular carcinoma; GBC, gallbladder carcinoma.

###### 

Subgroup analysis of OS

  Subgroups     No of studies   No of patients   Pooled HR (95% CI)   PHet        *I*^2^ (%)   *p*-value
  ------------- --------------- ---------------- -------------------- ----------- ------------ -----------
  Sample size                                                                                  
   ≤110         13              1,017            0.90 (0.58, 1.40)    0.0001      66.0         0.64
   \>110        11              2,396            1.46 (1.09, 1.94)    0.0006      66.0         0.01
  NOS score                                                                                    
   ≤7           11              1,037            0.99 (0.66, 1.47)    0.0001      68.0         0.94
   \>7          13              2,376            1.38 (0.99, 1.93)    0.0002      67.0         0.05
  Cutoff                                                                                       
   ≤10%         14              1,913            1.34 (0.96, 1.87)    \<0.00001   73.0         0.09
   \>10%        8               1,240            0.87 (0.52, 1.47)    \<0.00001   74.0         0.61
  NR            2               260              1.73 (1.00, 3.01)    0.43        0.0          0.05

**Abbreviations:** OS, overall survival; HR, hazard ratio; NOS, Newcastle--Ottawa Scale; NR, not reported.
